Search

everythinglearnresearchcommunity

for

Search:↓

Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.

Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.

Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

New medications could improve treatment for severe alopecia areata in Australia.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Botryococcus terribilis Ethanol Extract may reduce inflammation by changing gene expression in cells.

Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Skin pigmentation varies due to genetics, UV exposure, and medications, with treatments available but requiring medical advice.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.

Improving human hair follicle models is crucial for better hair loss treatments.

Belatacept may be a promising treatment for alopecia areata.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.

Stem cells slowed lung tumor growth but increased colon tumor growth in mice.

Microneedles improve drug delivery for skin diseases, enhancing treatment effectiveness and patient compliance.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.

New treatments are needed for non-scarring alopecia due to current limitations.

New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.